Evidence map›Paper›PMID 41199836›Full record

ArticleFrontiers in oncology2025

Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers.

Daphne J F Kluitmans, Janneke J T M Melis, Esmee van den Bossche, Jacob Ytsma, Jeroen A D M de Roos, Oscar P J van Linden, Yvonne Grobben, Jeffrey J Kooijman, Guido J R Zaman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daphne J F KluitmansOncolines B.V., Oss, Netherlands.
Janneke J T M MelisOncolines B.V., Oss, Netherlands.
Esmee van den BosscheOncolines B.V., Oss, Netherlands.
Jacob YtsmaOncolines B.V., Oss, Netherlands.
Jeroen A D M de RoosOncolines B.V., Oss, Netherlands.
Oscar P J van LindenDivision of Innovations in Human Health and Life Sciences, Amsterdam Institute of Molecular and Life Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Yvonne GrobbenOncolines B.V., Oss, Netherlands.
Jeffrey J KooijmanOncolines B.V., Oss, Netherlands.
Guido J R ZamanOncolines B.V., Oss, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Nemtabrutinib is a reversible inhibitor of both wild-type and acquired resistance-related mutant BTK. Since nemtabrutinib biochemically inhibits various kinases, new drug response biomarkers, cross-reactivities and differentiators may be identified. Methods: Nemtabrutinib was profiled in a large panel of cancer cell line viability assays. The sensitivity profile of nemtabrutinib was compared with the profiles of 135 kinase inhibitors across the same cell lines. Additionally, cell line sensitivity was related to gene mutation status, gene and protein expression levels, and gene dependency scores. Potential targets were explored using biochemical assays. Results: Sensitivity to nemtabrutinib is on average three times higher in Conclusion: Combined cancer cell panel and biochemical profiling reveals previously underappreciated cross-reactivities of nemtabrutinib indicating a potential application in MAPK-driven cancers.

Indexed as

BiacorebioinformaticsBruton’s tyrosine kinase (BTK)cancer cell line proliferationkinase inhibitorkinase profilingMAPK

Identifiers

PMID41199836
PMCPMC12586182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.